We use cookies for a better user experience. Read our Privacy Policy

I Agree

Industry Verticals »

All Categories

Insights »

About TMR »

Lipid Disorder Treatment Market

Schedule a Call

Lipid Disorder Treatment Market

Lipid Disorder Treatment Market (Drug Type- Atorvastatin, Fluvastatin, Rosuvastatin, Simvastatin, Pravastatin, and Other Drugs; Distribution Channel- Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies; Indication- Familial Combined Hyperlipidemia, Familial Defective Apolipoprotein B-100, Familial Dysbetalipoproteinemia, Familial Hypertriglyceridemia, Heterozygous Familial Hypercholesterolemia, and Other Indications) - Global Industry Analysis, Share, Size, Growth, Trends and Forecast 2017 - 2026

Emergence of various lifestyle diseases has been witnessed worldwide, especially among teens and people lying in the 50-60 years age group. Lipid disorders are largely caused due to high cholesterol and triglycerides, which ultimately can result in increased chances of heart diseases, which has prompted the development of safe and efficient treatments for lipid disorders. Moreover, smoking and drinking have largely contributed to the rising prevalence of lipid disorders and other cardiovascular diseases among men and women. This has fuelled demand for advanced treatments such as introduction of modern lipid lowering drugs. The demand for lipid disorder treatments has risen owing to occupational diseases caused by higher consumption of alcohol results in rising amount of bad cholesterol or LDL, irregular eating habits, lack of body exercises and improper medication.

global lipid disorder treatment market

Analysis of Transparency Market Research shows that the global market for lipid disorder treatment is expected to grow at an exceptional pace during the period of assessment. This growth is fuelled by rising demand for modern lipid metabolism disorder treatments coupled with increased chances of cardiovascular diseases across the globe. The global market for lipid disorder treatment is poised to register a value CAGR of 7.4% during the period of assessment, 2017-2026.

Several biopharma companies are focusing on developing effective solutions for treating lipid disorders. Companies involved in lipid disorder treatment market include Teva Pharmaceuticals, Mylan Pharmaceuticals, Inc., Kowa Pharmaceuticals America, Inc., Glenmark Pharmaceuticals Ltd., Sun Pharmaceuticals Industries Ltd., and Wockhardt Limited.

Sales of Drugs to Treat Lipid Disorders to Remain High in North America

United States has registered a higher number of people acquiring lipid disorders, especially among adults. Growing consumption of drugs such as atorvastatin and fluvastatin to treat hypercholesterolemia and other associated lipid disorders has been witnessed in the country. Several tests have been performed to identify patients who have a high risk of developing lipid disorders owing to family history or genetic disorders. According to American Academy of Pediatrics and National Heart, Lung and Blood Institute, atherosclerotic cardiovascular disease is a leading cause of death in the region.

This has pushed the use of prescription drugs in the region, making it imperative for pharma companies to increase their production rate and revise their production cycles. In addition, screening for lipid disorders in childhood has been initiated in the region, and as per study, a moderate percentage of children population in the United States is being affected by lipid disorders, that typically surface as the child reaches its teenage. This has presented potential opportunities for sale of drugs for the treatment of lipid disorders in North America, making it an attractive region from a business point of view.

Atorvastatin to Witness Increased Demand for Lipid Disorder Treatment

As the risk of developing lipid disorders increases, pharmaceutical companies have initiated drug enhancement, introduction of new drugs and conducting phase trials of these drugs on a large scale. Statins are considered to be highly effective in lowering the rate cardiovascular events. Most companies are focusing on mass production of atorvastatin as they are a highly effective low density lipoprotein lowering agents, LDL being the main cause of lipid disorders and associated heart diseases. The consumption of atorvastatin is expected to grow at a higher rate. Market for atorvastatin is poised to reach a value of over US$ 16 Bn by the end of the assessment period.

Changing Lifestyle and Hectic Schedule to Increase Growth Rate of Lipid Disorder Treatment Market

Lipid disorders are extensively caused due to obesity and high cholesterol. Obesity has become a prominent problem among a large chunk of the global populace. The changing lifestyle and the increase in consumption of alcohol and junk food have triggered obesity among a considerable populace. Thus, this aspect will bring considerable growth for the lipid disorder treatment market through the assessment period of 2017-2026.

  • Research and development activities by the players in the lipid disorder treatment market are bringing novel formulations and treatment options for lipid disorders to the forefront. This factor is helping in generating good revenues and eventually inviting growth for the lipid disorder treatment market. The increasing prevalence of familial combined hyperlipidemia may further boost the growth prospects of the lipid disorder treatment market.
  • A hectic lifestyle coupled with stress and tensions of everyday life has drifted individuals from fitness activities. Overconsumption of oily and junk food has also resulted in high prevalence of lipid disorders. Thus, all these factors may bring tremendous growth opportunities for the lipid disorder treatment market between 2017 and 2026.
  • The rising awareness about lipid disorders and the initiatives by the governments of various countries have led to an increase in the number of lipid disorder treatments. These factors may prove to be fruitful for the growth of the lipid disorder treatment market.  The growing cases of high cholesterol among children and adolescents will further bring promising growth for the lipid disorder treatment market.
  • The SARS-CoV-2 pandemic has resulted in tremendous changes across the landscapes of various businesses and sectors. The lipid disorder treatment market is no exception. The imposition of lockdown and border restrictions across numerous countries has resulted in tremendous losses. Thus, this aspect may harm the growth of the lipid disorder treatment market to a certain extent.

Market Segmentation

Region
  • North America
  • Latin America
  • Europe
  • Japan
  • APEJ
  • MEA

Drug Type
  • Atorvastatin
  • Fluvastatin
  • Rosuvastatin
  • Simvastatin
  • Pravastatin
  • Other Drugs

Distribution Channel
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Indication
  • Familial Combined Hyperlipidemia
  • Familial Defective Apolipoprotein B-100
  • Familial Dysbetalipoproteinemia
  • Familial Hypertriglyceridemia
  • Heterozygous Familial Hypercholesterolemia
  • Other Indications

    1. Global Outlook

    2. Global Lipid Disorder Treatment Market - Executive Summary

    3. Global Lipid Disorder Treatment Market Overview
         3.1. Introduction
                3.1.1. Global Lipid Disorder Treatment Market Taxonomy
                3.1.2. Global Lipid Disorder Treatment Market Definition
         3.2. Global Lipid Disorder Treatment Market Size (US$ Mn) and Forecast, 2012-2026
                3.2.1. Global Lipid Disorder Treatment Market Y-o-Y Growth
         3.3. Global Lipid Disorder Treatment Market Dynamics
         3.4. Supply Chain
         3.5. Cost Structure
         3.6. Porte's Five Forces Analysis
         3.7. Desirable Lipid Levels in Adults 
         3.8. Limiting Fat and Cholesterol in the Diet
         3.9. A Practical Approach to a Low-Cholesterol, Low-Saturated Fat Diet
         3.10. Cholesterol and Heart Disease By the Numbers 
         3.11. Screening for Elevated Cholesterol
         3.12. Lifestyle Interventions
         3.13. Treatment based on Group
         3.14. PEST Analysis
         3.15. Market Positioning and Behaviour Assessment 
         3.16. Investment Feasibility Index 
         3.17. Competitor Market Footprint Matrix
         3.18. Key Participants Market Presence (Intensity Map) By Region

    4. Global Lipid Disorder Treatment Market Analysis and Forecast 2012-2026 
         4.1. Global Lipid Disorder Treatment Market Size and Forecast By Drug Type, 2012-2026
                4.1.1. Atorvastatin Market Size and Forecast, 2012-2026
                         4.1.1.1. Revenue (US$ Mn) Comparison, By Region
                         4.1.1.2. Market Share Comparison, By Region
                         4.1.1.3. Y-o-Y growth Comparison, By Region
                4.1.2. Fluvastatin Market Size and Forecast, 2012-2026
                         4.1.2.1. Revenue (US$ Mn) Comparison, By Region
                         4.1.2.2. Market Share Comparison, By Region
                         4.1.2.3. Y-o-Y growth Comparison, By Region
                4.1.3. Rosuvastatin Market Size and Forecast, 2012-2026
                         4.1.3.1. Revenue (US$ Mn) Comparison, By Region
                         4.1.3.2. Market Share Comparison, By Region
                         4.1.3.3. Y-o-Y growth Comparison, By Region
                4.1.4. Simvastatin Market Size and Forecast, 2012-2026
                         4.1.4.1. Revenue (US$ Mn) Comparison, By Region
                         4.1.4.2. Market Share Comparison, By Region
                         4.1.4.3. Y-o-Y growth Comparison, By Region
                4.1.5. Pravastatin Market Size and Forecast, 2012-2026
                         4.1.5.1. Revenue (US$ Mn) Comparison, By Region
                         4.1.5.2. Market Share Comparison, By Region
                         4.1.5.3. Y-o-Y growth Comparison, By Region
                4.1.6. Other Drugs Market Size and Forecast, 2012-2026
                         4.1.6.1. Revenue (US$ Mn) Comparison, By Region
                         4.1.6.2. Market Share Comparison, By Region
                         4.1.6.3. Y-o-Y growth Comparison, By Region
         4.2. Global Lipid Disorder Treatment Market Size and Forecast By Distribution Channel, 2012-2026
                4.2.1. Retail Pharmacies Market Size and Forecast, 2012-2026
                         4.2.1.1. Revenue (US$ Mn) Comparison, By Region
                         4.2.1.2. Market Share Comparison, By Region
                         4.2.1.3. Y-o-Y growth Comparison, By Region
                4.2.2. Hospital Pharmacies Market Size and Forecast, 2012-2026
                         4.2.2.1. Revenue (US$ Mn) Comparison, By Region
                         4.2.2.2. Market Share Comparison, By Region
                         4.2.2.3. Y-o-Y growth Comparison, By Region
                4.2.3. Online Pharmacies Market Size and Forecast, 2012-2026
                         4.2.3.1. Revenue (US$ Mn) Comparison, By Region
                         4.2.3.2. Market Share Comparison, By Region
                         4.2.3.3. Y-o-Y growth Comparison, By Region
         4.3. Global Lipid Disorder Treatment Market Size and Forecast By Indication, 2012-2026
                4.3.1. Familial Combined Hyperlipidemia Market Size and Forecast, 2012-2026
                         4.3.1.1. Revenue (US$ Mn) Comparison, By Region
                         4.3.1.2. Market Share Comparison, By Region
                         4.3.1.3. Y-o-Y growth Comparison, By Region
                4.3.2. Familial Defective Apolipoprotein B-100 Market Size and Forecast, 2012-2026
                         4.3.2.1. Revenue (US$ Mn) Comparison, By Region
                         4.3.2.2. Market Share Comparison, By Region
                         4.3.2.3. Y-o-Y growth Comparison, By Region
                4.3.3. Familial Dysbetalipoproteinemia Market Size and Forecast, 2012-2026
                         4.3.3.1. Revenue (US$ Mn) Comparison, By Region
                         4.3.3.2. Market Share Comparison, By Region
                         4.3.3.3. Y-o-Y growth Comparison, By Region
                4.3.4. Familial Hypertriglyceridemia Market Size and Forecast, 2012-2026
                         4.3.4.1. Revenue (US$ Mn) Comparison, By Region
                         4.3.4.2. Market Share Comparison, By Region
                         4.3.4.3. Y-o-Y growth Comparison, By Region
                4.3.5. Heterozygous Familial Hypercholesterolemia Market Size and Forecast, 2012-2026
                         4.3.5.1. Revenue (US$ Mn) Comparison, By Region
                         4.3.5.2. Market Share Comparison, By Region
                         4.3.5.3. Y-o-Y growth Comparison, By Region
                4.3.6. Other Indications Market Size and Forecast, 2012-2026
                         4.3.6.1. Revenue (US$ Mn) Comparison, By Region
                         4.3.6.2. Market Share Comparison, By Region
                         4.3.6.3. Y-o-Y growth Comparison, By Region

    5. North America Lipid Disorder Treatment Market Size and Forecast, 2012-2026
         5.1. North America Outlook 
         5.2. North America Parent Market Outlook 
         5.3. North America Target Market Outlook 
         5.4. Revenue (US$ Mn) Comparison, By Country 
                5.4.1. US Market Size and Forecast (US$ Mn), 2012-2026
                5.4.2. Canada Market Size and Forecast (US$ Mn), 2012-2026
         5.5. Revenue (US$ Mn) Comparison, By Drug Type 
         5.6. Revenue (US$ Mn) Comparison, By Distribution Channel 
         5.7. Revenue (US$ Mn) Comparison, By Indication

    6. Latin America Lipid Disorder Treatment Market Size and Forecast, 2012-2026
         6.1. Latin America Outlook 
         6.2. Latin America Parent Market Outlook 
         6.3. Latin America Target Market Outlook 
         6.4. Revenue (US$ Mn) Comparison, By Country 
                6.4.1. Brazil Market Size and Forecast (US$ Mn), 2012-2026
                6.4.2. Mexico Market Size and Forecast (US$ Mn), 2012-2026
                6.4.3. Rest of Latin America Market Size and Forecast (US$ Mn), 2012-2026
         6.5. Revenue (US$ Mn) Comparison, By Drug Type 
         6.6. Revenue (US$ Mn) Comparison, By Distribution Channel 
         6.7. Revenue (US$ Mn) Comparison, By Indication

    7. Europe Lipid Disorder Treatment Market Size and Forecast, 2012-2026
         7.1. Europe Outlook 
         7.2. Europe Parent Market Outlook 
         7.3. Europe Target Market Outlook 
         7.4. Revenue (US$ Mn) Comparison, By Country 
                7.4.1. Germany Market Size and Forecast (US$ Mn), 2012-2026
                7.4.2. UK Market Size and Forecast (US$ Mn), 2012-2026
                7.4.3. France Market Size and Forecast (US$ Mn), 2012-2026
                7.4.4. Spain Market Size and Forecast (US$ Mn), 2012-2026
                7.4.5. Italy Market Size and Forecast (US$ Mn), 2012-2026
                7.4.6. Rest of Europe Market Size and Forecast (US$ Mn), 2012-2026
         7.5. Revenue (US$ Mn) Comparison, By Drug Type 
         7.6. Revenue (US$ Mn) Comparison, By Distribution Channel 
         7.7. Revenue (US$ Mn) Comparison, By Indication

    8. Japan Lipid Disorder Treatment Market Size and Forecast, 2012-2026
         8.1. Japan Outlook 
         8.2. Japan Parent Market Outlook 
         8.3. Japan Target Market Outlook 
         8.4. Japan Market Size and Forecast (US$ Mn), 2012-2026
         8.5. Revenue (US$ Mn) Comparison, By Drug Type 
         8.6. Revenue (US$ Mn) Comparison, By Distribution Channel 
         8.7. Revenue (US$ Mn) Comparison, By Indication

    9. APEJ Lipid Disorder Treatment Market Size and Forecast, 2012-2026
         9.1. APEJ Outlook 
         9.2. APEJ Parent Market Outlook 
         9.3. APEJ Target Market Outlook 
         9.4. Revenue (US$ Mn) Comparison, By Country 
                9.4.1. China Market Size and Forecast (US$ Mn), 2012-2026
                9.4.2. India Market Size and Forecast (US$ Mn), 2012-2026
                9.4.3. Thailand Market Size and Forecast (US$ Mn), 2012-2026
                9.4.4. Singapore Market Size and Forecast (US$ Mn), 2012-2026
                9.4.5. Australia Market Size and Forecast (US$ Mn), 2012-2026
                9.4.6. Rest of APEJ Market Size and Forecast (US$ Mn), 2012-2026
         9.5. Revenue (US$ Mn) Comparison, By Drug Type 
         9.6. Revenue (US$ Mn) Comparison, By Distribution Channel 
         9.7. Revenue (US$ Mn) Comparison, By Indication

    10. MEA Lipid Disorder Treatment Market Size and Forecast, 2012-2026
         10.1. MEA Outlook 
         10.2. MEA Parent Market Outlook 
         10.3. MEA Target Market Outlook 
         10.4. Revenue (US$ Mn) Comparison, By Country 
                10.4.1. GCC Countries Market Size and Forecast (US$ Mn), 2012-2026
                10.4.2. South Africa Market Size and Forecast (US$ Mn), 2012-2026
                10.4.3. Nigeria Market Size and Forecast (US$ Mn), 2012-2026
                10.4.4. Rest of MEA Market Size and Forecast (US$ Mn), 2012-2026
         10.5. Revenue (US$ Mn) Comparison, By Drug Type 
         10.6. Revenue (US$ Mn) Comparison, By Distribution Channel 
         10.7. Revenue (US$ Mn) Comparison, By Indication

    11. Global Lipid Disorder Treatment Market Company Share, Competition Landscape and Company Profiles
         11.1. Global Lipid Disorder Treatment Market Company Share Analysis
         11.2. Global Lipid Disorder Treatment Market Competition Landscape
         11.3. Global Lipid Disorder Treatment Market Company Profiles
                11.3.1. Pfizer, Inc
                11.3.2. Novartis AG
                11.3.3. Astrazeneca Plc
                11.3.4. Merck & Co.
                11.3.5. Emcure Pharmaceuticals Ltd.
                11.3.6. Ranbaxy Laboratories Ltd. 
                11.3.7. Teva Pharmaceuticals
                11.3.8. Mylan Pharmaceuticals, Inc.
                11.3.9. Kowa Pharmaceuticals America, Inc.
                11.3.10. Glenmark Pharmaceuticals Ltd.
                11.3.11. Sun Pharmaceuticals Industries Ltd.
                11.3.12. Wockhardt Limited

    12. Key Takeaways

    13. Research Methodology

    14. Disclaimer

    List of Table

    TABLE 1 Global Lipid Disorder Treatment Market Value (US$ Mn), 2012-2017
    TABLE 2 Global Lipid Disorder Treatment Market Value (US$ Mn), 2018-2026
    TABLE 3 Global Lipid Disorder Treatment Market Value (US$ Mn) and Y-o-Y, 2017-2026
    TABLE 4 Global Atorvastatin Segment Value (US$ Mn), By Region 2012-2017
    TABLE 5 Global Atorvastatin Segment Value (US$ Mn), By Region 2018-2026
    TABLE 6 Global Atorvastatin Segment Market Share, By Region 2012-2017
    TABLE 7 Global Atorvastatin Segment Market Share, By Region 2018-2026
    TABLE 8 Global Atorvastatin Segment Y-o-Y, By Region 2017-2026
    TABLE 9 Global Fluvastatin Segment Value (US$ Mn), By Region 2012-2017
    TABLE 10 Global Fluvastatin Segment Value (US$ Mn), By Region 2018-2026
    TABLE 11 Global Fluvastatin Segment Market Share, By Region 2012-2017
    TABLE 12 Global Fluvastatin Segment Market Share, By Region 2018-2026
    TABLE 13 Global Fluvastatin Segment Y-o-Y, By Region 2017-2026
    TABLE 14 Global Rosuvastatin Segment Value (US$ Mn), By Region 2012-2017
    TABLE 15 Global Rosuvastatin Segment Value (US$ Mn), By Region 2018-2026
    TABLE 16 Global Rosuvastatin Segment Market Share, By Region 2012-2017
    TABLE 17 Global Rosuvastatin Segment Market Share, By Region 2018-2026
    TABLE 18 Global Rosuvastatin Segment Y-o-Y, By Region 2017-2026
    TABLE 19 Global Simvastatin Segment Value (US$ Mn), By Region 2012-2017
    TABLE 20 Global Simvastatin Segment Value (US$ Mn), By Region 2018-2026
    TABLE 21 Global Simvastatin Segment Market Share, By Region 2012-2017
    TABLE 22 Global Simvastatin Segment Market Share, By Region 2018-2026
    TABLE 23 Global Simvastatin Segment Y-o-Y, By Region 2017-2026
    TABLE 24 Global Pravastatin Segment Value (US$ Mn), By Region 2012-2017
    TABLE 25 Global Pravastatin Segment Value (US$ Mn), By Region 2018-2026
    TABLE 26 Global Pravastatin Segment Market Share, By Region 2012-2017
    TABLE 27 Global Pravastatin Segment Market Share, By Region 2018-2026
    TABLE 28 Global Pravastatin Segment Y-o-Y, By Region 2017-2026
    TABLE 29 Global Other Drugs Segment Value (US$ Mn), By Region 2012-2017
    TABLE 30 Global Other Drugs Segment Value (US$ Mn), By Region 2018-2026
    TABLE 31 Global Other Drugs Segment Market Share, By Region 2012-2017
    TABLE 32 Global Other Drugs Segment Market Share, By Region 2018-2026
    TABLE 33 Global Other Drugs Segment Y-o-Y, By Region 2017-2026
    TABLE 34 Global Retail Pharmacies Segment Value (US$ Mn), By Region 2012-2017
    TABLE 35 Global Retail Pharmacies Segment Value (US$ Mn), By Region 2018-2026
    TABLE 36 Global Retail Pharmacies Segment Market Share, By Region 2012-2017
    TABLE 37 Global Retail Pharmacies Segment Market Share, By Region 2018-2026
    TABLE 38 Global Retail Pharmacies Segment Y-o-Y, By Region 2017-2026
    TABLE 39 Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2012-2017
    TABLE 40 Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2018-2026
    TABLE 41 Global Hospital Pharmacies Segment Market Share, By Region 2012-2017
    TABLE 42 Global Hospital Pharmacies Segment Market Share, By Region 2018-2026
    TABLE 43 Global Hospital Pharmacies Segment Y-o-Y, By Region 2017-2026
    TABLE 44 Global Online Pharmacies Segment Value (US$ Mn), By Region 2012-2017
    TABLE 45 Global Online Pharmacies Segment Value (US$ Mn), By Region 2018-2026
    TABLE 46 Global Online Pharmacies Segment Market Share, By Region 2012-2017
    TABLE 47 Global Online Pharmacies Segment Market Share, By Region 2018-2026
    TABLE 48 Global Online Pharmacies Segment Y-o-Y, By Region 2017-2026
    TABLE 49 Global Familial Combined Hyperlipidemia Segment Value (US$ Mn), By Region 2012-2017
    TABLE 50 Global Familial Combined Hyperlipidemia Segment Value (US$ Mn), By Region 2018-2026
    TABLE 51 Global Familial Combined Hyperlipidemia Segment Market Share, By Region 2012-2017
    TABLE 52 Global Familial Combined Hyperlipidemia Segment Market Share, By Region 2018-2026
    TABLE 53 Global Familial Combined Hyperlipidemia Segment Y-o-Y, By Region 2017-2026
    TABLE 54 Global Familial Defective Apolipoprotein B-100 Segment Value (US$ Mn), By Region 2012-2017
    TABLE 55 Global Familial Defective Apolipoprotein B-100 Segment Value (US$ Mn), By Region 2018-2026
    TABLE 56 Global Familial Defective Apolipoprotein B-100 Segment Market Share, By Region 2012-2017
    TABLE 57 Global Familial Defective Apolipoprotein B-100 Segment Market Share, By Region 2018-2026
    TABLE 58 Global Familial Defective Apolipoprotein B-100 Segment Y-o-Y, By Region 2017-2026
    TABLE 59 Global Familial Dysbetalipoproteinemia Segment Value (US$ Mn), By Region 2012-2017
    TABLE 60 Global Familial Dysbetalipoproteinemia Segment Value (US$ Mn), By Region 2018-2026
    TABLE 61 Global Familial Dysbetalipoproteinemia Segment Market Share, By Region 2012-2017
    TABLE 62 Global Familial Dysbetalipoproteinemia Segment Market Share, By Region 2018-2026
    TABLE 63 Global Familial Dysbetalipoproteinemia Segment Y-o-Y, By Region 2017-2026
    TABLE 64 Global Familial Hypertriglyceridemia Segment Value (US$ Mn), By Region 2012-2017
    TABLE 65 Global Familial Hypertriglyceridemia Segment Value (US$ Mn), By Region 2018-2026
    TABLE 66 Global Familial Hypertriglyceridemia Segment Market Share, By Region 2012-2017
    TABLE 67 Global Familial Hypertriglyceridemia Segment Market Share, By Region 2018-2026
    TABLE 68 Global Familial Hypertriglyceridemia Segment Y-o-Y, By Region 2017-2026
    TABLE 69 Global Heterozygous Familial Hypercholesterolemia Segment Value (US$ Mn), By Region 2012-2017
    TABLE 70 Global Heterozygous Familial Hypercholesterolemia Segment Value (US$ Mn), By Region 2018-2026
    TABLE 71 Global Heterozygous Familial Hypercholesterolemia Segment Market Share, By Region 2012-2017
    TABLE 72 Global Heterozygous Familial Hypercholesterolemia Segment Market Share, By Region 2018-2026
    TABLE 73 Global Heterozygous Familial Hypercholesterolemia Segment Y-o-Y, By Region 2017-2026
    TABLE 74 Global Other Indications Segment Value (US$ Mn), By Region 2012-2017
    TABLE 75 Global Other Indications Segment Value (US$ Mn), By Region 2018-2026
    TABLE 76 Global Other Indications Segment Market Share, By Region 2012-2017
    TABLE 77 Global Other Indications Segment Market Share, By Region 2018-2026
    TABLE 78 Global Other Indications Segment Y-o-Y, By Region 2017-2026
    TABLE 79 North America Lipid Disorder Treatment Market Value (US$ Mn), By Country 2012-2017
    TABLE 80 North America Lipid Disorder Treatment Market Value (US$ Mn), By Country 2018-2026
    TABLE 81 North America Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2012-2017
    TABLE 82 North America Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2018-2026
    TABLE 83 North America Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
    TABLE 84 North America Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
    TABLE 85 North America Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2012-2017
    TABLE 86 North America Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2018-2026
    TABLE 87 Latin America Lipid Disorder Treatment Market Value (US$ Mn), By Country 2012-2017
    TABLE 88 Latin America Lipid Disorder Treatment Market Value (US$ Mn), By Country 2018-2026
    TABLE 89 Latin America Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2012-2017
    TABLE 90 Latin America Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2018-2026
    TABLE 91 Latin America Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
    TABLE 92 Latin America Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
    TABLE 93 Latin America Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2012-2017
    TABLE 94 Latin America Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2018-2026
    TABLE 95 Europe Lipid Disorder Treatment Market Value (US$ Mn), By Country 2012-2017
    TABLE 96 Europe Lipid Disorder Treatment Market Value (US$ Mn), By Country 2018-2026
    TABLE 97 Europe Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2012-2017
    TABLE 98 Europe Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2018-2026
    TABLE 99 Europe Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
    TABLE 100 Europe Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
    TABLE 101 Europe Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2012-2017
    TABLE 102 Europe Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2018-2026
    TABLE 103 Japan Lipid Disorder Treatment Market Value (US$ Mn), By Country 2012-2017
    TABLE 104 Japan Lipid Disorder Treatment Market Value (US$ Mn), By Country 2018-2026
    TABLE 105 Japan Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2012-2017
    TABLE 106 Japan Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2018-2026
    TABLE 107 Japan Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
    TABLE 108 Japan Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
    TABLE 109 Japan Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2012-2017
    TABLE 110 Japan Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2018-2026
    TABLE 111 APEJ Lipid Disorder Treatment Market Value (US$ Mn), By Country 2012-2017
    TABLE 112 APEJ Lipid Disorder Treatment Market Value (US$ Mn), By Country 2018-2026
    TABLE 113 APEJ Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2012-2017
    TABLE 114 APEJ Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2018-2026
    TABLE 115 APEJ Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
    TABLE 116 APEJ Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
    TABLE 117 APEJ Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2012-2017
    TABLE 118 APEJ Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2018-2026
    TABLE 119 MEA Lipid Disorder Treatment Market Value (US$ Mn), By Country 2012-2017
    TABLE 120 MEA Lipid Disorder Treatment Market Value (US$ Mn), By Country 2018-2026
    TABLE 121 MEA Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2012-2017
    TABLE 122 MEA Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2018-2026
    TABLE 123 MEA Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
    TABLE 124 MEA Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
    TABLE 125 MEA Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2012-2017
    TABLE 126 MEA Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2018-2026

    List of Figure

    FIG. 1 Global Lipid Disorder Treatment Market Value (US$ Mn), 2012-2017
    FIG. 2 Global Lipid Disorder Treatment Market Value (US$ Mn) Forecast, 2018-2026
    FIG. 3 Global Lipid Disorder Treatment Market Value (US$ Mn) and Y-o-Y, 2017-2026
    FIG. 4 Global Atorvastatin Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 5 Global Atorvastatin Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 6 Global Atorvastatin Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 7 Global Fluvastatin Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 8 Global Fluvastatin Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 9 Global Fluvastatin Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 10 Global Rosuvastatin Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 11 Global Rosuvastatin Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 12 Global Rosuvastatin Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 13 Global Simvastatin Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 14 Global Simvastatin Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 15 Global Simvastatin Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 16 Global Pravastatin Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 17 Global Pravastatin Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 18 Global Pravastatin Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 19 Global Other Drugs Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 20 Global Other Drugs Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 21 Global Other Drugs Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 22 Global Retail Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 23 Global Retail Pharmacies Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 24 Global Retail Pharmacies Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 25 Global Hospital Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 26 Global Hospital Pharmacies Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 27 Global Hospital Pharmacies Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 28 Global Online Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 29 Global Online Pharmacies Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 30 Global Online Pharmacies Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 31 Global Familial Combined Hyperlipidemia Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 32 Global Familial Combined Hyperlipidemia Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 33 Global Familial Combined Hyperlipidemia Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 34 Global Familial Defective Apolipoprotein B-100 Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 35 Global Familial Defective Apolipoprotein B-100 Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 36 Global Familial Defective Apolipoprotein B-100 Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 37 Global Familial Dysbetalipoproteinemia Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 38 Global Familial Dysbetalipoproteinemia Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 39 Global Familial Dysbetalipoproteinemia Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 40 Global Familial Hypertriglyceridemia Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 41 Global Familial Hypertriglyceridemia Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 42 Global Familial Hypertriglyceridemia Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 43 Global Heterozygous Familial Hypercholesterolemia Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 44 Global Heterozygous Familial Hypercholesterolemia Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 45 Global Heterozygous Familial Hypercholesterolemia Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 46 Global Other Indications Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 47 Global Other Indications Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 48 Global Other Indications Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 49 North America Lipid Disorder Treatment Market Value (US$ Mn), By Country 2012-2017
    FIG. 50 North America Lipid Disorder Treatment Market Value (US$ Mn), By Country 2018-2026
    FIG. 51 North America Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2012-2017
    FIG. 52 North America Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2018-2026
    FIG. 53 North America Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
    FIG. 54 North America Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
    FIG. 55 North America Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2012-2017
    FIG. 56 North America Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2018-2026
    FIG. 57 Latin America Lipid Disorder Treatment Market Value (US$ Mn), By Country 2012-2017
    FIG. 58 Latin America Lipid Disorder Treatment Market Value (US$ Mn), By Country 2018-2026
    FIG. 59 Latin America Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2012-2017
    FIG. 60 Latin America Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2018-2026
    FIG. 61 Latin America Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
    FIG. 62 Latin America Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
    FIG. 63 Latin America Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2012-2017
    FIG. 64 Latin America Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2018-2026
    FIG. 65 Europe Lipid Disorder Treatment Market Value (US$ Mn), By Country 2012-2017
    FIG. 66 Europe Lipid Disorder Treatment Market Value (US$ Mn), By Country 2018-2026
    FIG. 67 Europe Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2012-2017
    FIG. 68 Europe Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2018-2026
    FIG. 69 Europe Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
    FIG. 70 Europe Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
    FIG. 71 Europe Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2012-2017
    FIG. 72 Europe Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2018-2026
    FIG. 73 Japan Lipid Disorder Treatment Market Value (US$ Mn), By Country 2012-2017
    FIG. 74 Japan Lipid Disorder Treatment Market Value (US$ Mn), By Country 2018-2026
    FIG. 75 Japan Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2012-2017
    FIG. 76 Japan Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2018-2026
    FIG. 77 Japan Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2012-2017
    FIG. 78 Japan Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
    FIG. 79 Japan Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2012-2017
    FIG. 80 Japan Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2018-2026
    FIG. 81 APEJ Lipid Disorder Treatment Market Value (US$ Mn), By Country 2012-2017
    FIG. 82 APEJ Lipid Disorder Treatment Market Value (US$ Mn), By Country 2018-2026
    FIG. 83 APEJ Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2012-2017
    FIG. 84 APEJ Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2018-2026
    FIG. 85 APEJ Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
    FIG. 86 APEJ Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
    FIG. 87 APEJ Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2012-2017
    FIG. 88 APEJ Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2018-2026
    FIG. 89 MEA Lipid Disorder Treatment Market Value (US$ Mn), By Country 2012-2017
    FIG. 90 MEA Lipid Disorder Treatment Market Value (US$ Mn), By Country 2018-2026
    FIG. 91 MEA Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2012-2017
    FIG. 92 MEA Lipid Disorder Treatment Market Value (US$ Mn), By Drug Type 2018-2026
    FIG. 93 MEA Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
    FIG. 94 MEA Lipid Disorder Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
    FIG. 95 MEA Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2012-2017
    FIG. 96 MEA Lipid Disorder Treatment Market Value (US$ Mn), By Indication 2018-2026

Copyright © Transparency Market Research, Inc. All Rights reserved